

# Supplementary material for the financial results for the first quarter of the year ending March 31, 2024

---

**August 2023**  
(Stock code: 4553)

# Notes to and summary of the disclosure of financial results for 2024/03 1Q

## Notes

- As the fiscal year-end dates of Towa HD and Sunsho Pharmaceutical were changed for consolidated results during the fiscal year ended March 2023, the subsidiaries' first three-month period of the fiscal year ending March 31, 2024 is from April 1, 2023 to June 30, 2023.
- For the purpose of comparing the results for 2024/03 1Q with those for the same months (April to June) of the previous year, the results figures of Towa HD and Sunsho Pharmaceutical for 2023/03 1Q are disclosed as reference figures, with April 1 to June 30, 2022 replacing January 1 to March 31, 2022 as the first three-month period. In this document, these figures have been labeled “2023/03 1Q (adjusted period).”
- Towa HD's results figures for “2023/03 1Q (adjusted period)” have been calculated by subtracting the yen-based results for the period from January 1 to March 31, 2022, from the yen-based results for the period from January 1 to June 30, 2022, for convenience of translating local currency-based figures to yen-based figures. Therefore, the figures for “2023/03 1Q (adjusted period)” converted using the euro/yen exchange rate during the period from April 1 to June 30, 2022, do not coincide with the local currency-based figures for said period.

# Notes to and summary of the disclosure of financial results for 2024/03 1Q

## Summary

- **Net sales and profit increased** year on year at the overall consolidated level

Fiscal period	2024/03 1Q (Overseas & Sunsho: from April 2023 to June 2023)		2023/03 1Q (adjusted period) (Overseas & Sunsho: from April 2022 to June 2022)	2023/03 1Q (Overseas & Sunsho: from January 2022 to March 2022)	
	(JPY billion)	YOY change (%)	(JPY billion)	(JPY billion)	YOY change (%)
Net sales	54.5	+ 18.1	46.1	45.3	+ 5.7
Operating profit	4.0	+ 130.2	1.7	1.8	- 69.8

- **Production volume** (Towa Pharma non-consolidated; tablets and capsules only)  
→ **Approx. 3.4 billion tablets, up approx. 22.0%** year on year
- **Sales volume** (Towa Pharma non-consolidated; tablets and capsules only)  
→ **Approx. 3.23 billion tablets, up approx. 15.4%** year on year
- **Increases in raw material costs and utilities expenses** (Towa Pharma non-consolidated)
  - Raw materials: Increased by several percentage points year on year due to a weaker yen and higher resource prices
  - Utilities expenses: Increased by approx. 37.6% year on year.  
Utilities expenses accounted for approx. 2.5% of total manufacturing costs.

# Table of contents

- 1. Outline of financial results for 2024/03 1Q**
- 2. Outline of financial results for 2024/03 1Q – Progress rate**
- 3. Balance sheets, capital expenditure and depreciation**

# Table of contents

## 1. Outline of financial results for 2024/03 1Q

**Consolidated**

**Segment information**

**Domestic segment**

**Breakdown**

**Net sales by supplement year (Towa non-consolidated)**

**Net sales by distribution channel (Towa non-consolidated)**

**Number of customers by customer segment (Towa non-consolidated)**

**Selling, general and administrative expenses (Domestic segment)**

**Overseas segment**

**By region**

## 2. Outline of financial results for 2024/03

1Q – Progress rate

## 3. Balance sheets, capital expenditure and depreciation

# Outline of financial results for 2024/03 1Q (Consolidated)

- \* Comments below are on the comparison between 2024/03 1Q and 2023/03 1Q (adjusted period):
- Both sales and profit increased due to the strength of Towa Pharmaceutical and Sunsho Pharmaceutical in Japan, strong BtoB in Europe, and a weaker yen.
  - Ordinary profit: Increased due mainly to a gain on valuation of derivatives

(JPY million, %)

Fiscal period	2024/03 1Q			2023/03 1Q (adjusted period) (Overseas & Sunsho: April–June)		2023/03 1Q (Overseas & Sunsho: January–March)		
	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Net sales	54,548	100.0	+ 18.1	46,169	100.0	45,372	100.0	+ 5.7
Cost of sales	34,539	63.3	+ 17.8	29,314	63.5	28,885	63.7	+ 17.0
SGA	15,912	29.2	+ 5.6	15,074	32.7	14,650	32.3	+ 20.4
Operating profit	4,096	7.5	+ 130.2	1,779	3.9	1,836	4.0	– 69.8
Ordinary profit	6,959	12.8	+ 199.5	2,323	5.0	2,469	5.4	– 68.0
Profit attributable to owners of parent	4,750	8.7	+ 180.1	1,696	3.7	1,373	3.0	– 74.1

Exchange rate at end of period (TTM) USD 1	2024/03 1Q	2023/03 4Q	2023/03 1Q	2022/03 4Q	Exchange rate during period (TTM) EUR 1	2024/03 1Q	2023/03 April–June	2023/03 January–March
	JPY 144.99	JPY 133.53	JPY 136.68	JPY 122.39		JPY 149.47	JPY 138.12	JPY 130.39

- Notes: 1. The first three-month period for Towa HD and Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.  
2. For 2024/03 1Q, the USD/JPY exchange rate at the end of the period is the rate as of June 30, 2023, and the EUR/JPY exchange rate during the period is the average rate for the period from April 1, 2023 to June 30, 2023.

# Outline of financial results for 2024/03 1Q

## (Segment information)

(JPY million)

Item	Reportable segment			Adjustment (Goodwill amortization, etc.)	Consolidated
	Domestic	Overseas	Total		
	Towa Pharmaceutical J-Dolph Pharmaceutical Daichi Kasei Greencaps Pharmaceutical Sunsho Pharmaceutical	Towa HD			
Net sales	43,005	11,579	54,584	– 36	54,548
Cost of sales	26,576	7,962	34,539	–	34,539
SGA	11,237	3,645	14,882	1,029	15,912
Segment profit	5,191	– 28	5,162	– 1,066	4,096

- Notes: 1. The first three-month period for Towa HD and Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.  
 2. Adjustments include goodwill amortization and internal transactions between Towa Pharmaceutical and Towa HD.  
 3. Goodwill amortization: Towa HD JPY 230 million; Sunsho Pharmaceutical JPY 815 million

# Outline of financial results for 2024/03 1Q

## (Domestic segment)

- \* Comments below are on the comparison between 2024/03 1Q and 2023/03 1Q (adjusted period):
- **Net sales:** Increased due to the growth in sales volume at Towa Pharmaceutical mainly for new items and strong sales at Sunsho Pharmaceutical
  - **Segment profit:** Increased due to sales growth and a drop in the cost of sales ratio on the back of improved sales mix at Towa Pharmaceutical

(JPY million, %)

Fiscal period	Domestic segment (Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, Sunsho Pharmaceutical)							
	2024/03 1Q			2023/03 1Q (adjusted period) (Sunsho: April–June)		2023/03 1Q (Sunsho: January–March)		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Net sales	43,005	100.0	+ 19.2	36,067	100.0	35,570	100.0	+ 4.5
Cost of sales	26,576	61.8	+ 18.6	22,408	62.1	22,225	62.5	+ 19.8
SGA	11,237	26.1	+ 4.1	10,794	29.9	10,765	30.3	+ 16.5
Segment profit	5,191	12.1	+ 81.2	2,864	7.9	2,579	7.3	– 58.6

Notes: 1. The first three-month period for Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.



# Outline of financial results for 2024/03 1Q

## (Domestic segment, breakdown)

(JPY million, %)

Fiscal period	Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical					
	2024/03 1Q			2023/03 1Q		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Net sales	36,524	100.0	+ 19.3	30,620	100.0	- 10.0
Cost of sales	21,660	59.3	+ 18.2	18,332	59.9	- 1.2
SGA	10,271	28.1	+ 2.4	10,031	32.8	+ 8.5
Segment profit	4,592	12.6	+ 103.5	2,256	7.4	- 63.8

# Outline of financial results for 2024/03 1Q


## (Domestic segment, breakdown)

(JPY million, %)


Fiscal period	Sunsho Pharmaceutical						
	2024/03 1Q			2023/03 1Q (adjusted period) (April–June)		2023/03 1Q (January–March)	
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)
Net sales	6,480	100.0	+ 19.0	5,447	100.0	4,950	100.0
Cost of sales	4,916	75.9	+ 20.6	4,076	74.8	3,893	78.6
SGA	965	14.9	+ 26.6	763	14.0	733	14.8
Segment profit	598	9.2	– 1.6	608	11.2	323	6.5

- Notes: 1. The first three-month period for Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.

# Net sales by supplement year (Towa non-consolidated)



# Net sales by distribution channel (Towa non-consolidated)



■ Direct sales ■ Sales agent ■ Wholesaler ■ Other (consignment, sales by other companies, exports)

Figures in brackets indicate number of sales offices

# Number of customers by customer segment (Towa non-consolidated)

(Customer, %)

Customer segment	Number of medical institutions	2024/03					2023/03	
		Number of customers	Coverage (%)	Transaction amount % mix (%)	Change in number of customers	Change in transaction amount	Number of customers	Transaction amount % mix (%)
Hospitals	approx. 8,200	7,587	92.7	10.5	+ 134	+ 11.0	7,453	11.2
DPC	approx. 1,760	1,740	98.8	6.2	+ 24	+ 10.8	1,716	6.7
Clinics	approx. 105,800	30,722	29.0	11.7	+ 818	+ 12.9	29,904	12.3
Pharmacies	approx. 61,700	59,560	96.5	77.7	+ 1,852	+ 21.1	57,708	76.3
Total	approx. 175,700	97,869	55.7	100.0	+ 2,804	+ 19.0	95,065	100.0

(Excludes transactions by other companies)

Note: The number of medical institutions is calculated with reference to Nihon Ultmarc's national medical institution data.

# Selling, general and administrative expenses (Domestic segment)

(JPY million, %)

Fiscal period	Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, Sunsho Pharmaceutical					
	2024/03 1Q			2023/03 1Q (adjusted period) (Sunsho: April–June)		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Personnel	4,520	10.5	+ 2.8	4,396	12.2	+ 9.7
Advertising	170	0.4	– 8.9	187	0.5	– 43.5
Packing & freight	707	1.6	+ 2.8	688	1.9	+ 14.1
Commissions paid	1,243	2.9	+ 28.4	968	2.7	+ 82.0
R&D	2,778	6.5	– 5.4	2,936	8.1	+ 36.7
Depreciation	342	0.8	+ 11.5	306	0.9	+ 24.3
Other	1,474	3.4	+ 12.5	1,310	3.6	– 4.5
SGA	11,237	26.1	+ 4.1	10,794	29.9	+ 16.8

- Notes: 1. The first three-month period for Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.  
3. Expenses arising in the R&D Division have been reclassified as R&D expenses.

# Outline of financial results for 2024/03 1Q (Overseas segment)

- \* Comments below are on the comparison between 2024/03 1Q and 2023/03 1Q (adjusted period):
- **Net sales:** Increased mainly due to strong BtoB in Europe and the weaker yen
  - **Segment profit:** The loss decreased due to sales growth despite a rise in the cost of sales ratio due to a change in the sales mix in Europe.

(JPY million, %)

Fiscal period	Overseas segment (Towa HD)							
	2024/03 1Q			2023/03 1Q (adjusted period) (April–June)		2023/03 1Q (January–March)		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Net sales	11,579	100.0	+ 14.6	10,101	100.0	9,801	100.0	+ 10.1
Cost of sales	7,962	68.8	+ 15.3	6,905	68.4	6,660	67.9	+ 8.8
SGA	3,645	31.5	+ 12.1	3,251	32.2	2,867	29.3	+ 5.2
Segment profit (loss)	– 28	– 0.2	–	– 56	– 0.6	273	2.8	+ 424.6

Exchange rate during period (TTM) EUR 1	2024/03 1Q	2023/03 April–June	2023/03 January–March
	JPY 149.47	JPY 138.12	JPY 130.39

- Notes: 1. The first three-month period for Towa HD is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.

# Outline of financial results for 2024/03 1Q

(Overseas segment, by region)

(JPY million, %)

Fiscal period	Towa HD Europe							
	2024/03 1Q			2023/03 1Q (adjusted period) (April–June)		2023/03 1Q (January–March)		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Net sales	6,668	100.0	+ 19.8	5,566	100.0	5,366	100.0	+ 13.2
Cost of sales	4,478	67.2	+ 30.2	3,438	61.8	3,445	64.2	+ 15.7
SGA	2,582	38.7	+ 12.3	2,300	41.3	2,032	37.9	+ 5.5
Segment loss	– 392	– 5.9	–	– 172	– 3.1	– 112	– 2.1	–

Exchange rate during period (TTM) EUR 1	2024/03 1Q	2023/03 April–June	2023/03 January–March
		JPY 149.47	JPY 138.12

- Notes: 1. The first three-month period for Towa HD is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.



# Outline of financial results for 2024/03 1Q

(Overseas segment, by region)

(JPY million, %)

Fiscal period	Towa HD U.S.							
	2024/03 1Q			2023/03 1Q (adjusted period) (April–June)		2023/03 1Q (January–March)		
Item	(JPY million)	Percentage of net sales (%)	YOY change (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	YOY change (%)
Net sales	4,911	100.0	+ 8.3	4,534	100.0	4,435	100.0	+ 6.6
Cost of sales	3,484	71.0	+ 0.5	3,467	76.5	3,214	72.5	+ 2.3
SGA	1,062	21.6	+ 11.7	951	21.0	835	18.8	+ 4.4
Segment profit	364	7.4	+ 213.3	116	2.6	385	8.7	+ 77.2

Exchange rate during period (TTM) EUR 1	2024/03 1Q	2023/03 April–June	2023/03 January–March
		JPY 149.47	JPY 138.12

- Notes: 1. The first three-month period for Towa HD is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.

# Table of contents

1. Outline of financial results for 2024/03 1Q

**2. Outline of financial results for 2024/03**

**1Q – Progress rate**

**Consolidated**

**Domestic segment**

**Breakdown**

**Overseas segment**

**By region**

**Trend of R&D expenses**

3. Balance sheets, capital expenditure and depreciation

# Outline of financial results for 2024/03 1Q – Progress rate (Consolidated)

- **Net sales:** The progress rate was good both in Japan and overseas.
- **Operating profit:** The progress rate was good despite a worse-than-expected cost of sales ratio at Towa Pharmaceutical.

(JPY million, %)

Fiscal period	2024/03							
	1Q Results		First Half Plan			Full-year Plan		
Item	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)
Net sales	54,548	100.0	104,600	100.0	52.1	216,300	100.0	25.2
Cost of sales	34,539	63.3	65,800	62.9	52.5	136,600	63.2	25.3
SGA	15,912	29.2	33,000	31.5	48.2	67,900	31.4	23.4
Operating profit	4,096	7.5	5,800	5.5	70.6	11,800	5.5	34.7
Ordinary profit	6,959	12.8	5,600	5.4	124.3	11,500	5.3	60.5
Profit attributable to owners of parent	4,750	8.7	3,400	3.3	139.7	6,900	3.2	68.8

Exchange rate (TTM) EUR 1	Rate during 2024/03 1Q	Assumed rate for 2024/03
		JPY 149.47

Notes: 1. The first three-month period for Towa HD and Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.

# Outline of financial results for 2024/03 1Q – Progress rate

## (Domestic segment)

- **Net sales:** The progress rate was good overall.
- **Segment profit:** The progress rate was good despite a rise in the cost of sales ratio due to a worse-than-expected sales mix at Towa Pharmaceutical.

(JPY million, %)

Fiscal period	Domestic segment (Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical, Sunsho Pharmaceutical)							
	2024/03 1Q Results		2024/03 First Half Plan			2024/03 Full-year Plan		
Item	JPY million	Percentage of net sales (%)	JPY million	Percentage of net sales (%)	Progress rate (%)	JPY million	Percentage of net sales (%)	Progress rate (%)
Net sales	43,005	100.0	82,900	100.0	51.9	171,900	100.0	25.0
Cost of sales	26,576	61.8	50,800	61.3	52.3	106,100	61.7	25.0
SGA	11,237	26.1	24,100	29.1	46.6	50,000	29.1	22.5
Segment profit	5,191	12.1	8,000	9.7	64.9	15,800	9.2	32.9

Notes: 1. The first three-month period for Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.

# Outline of financial results for 2024/03 1Q – Progress rate

(Domestic segment, breakdown)

(JPY million, %)

Fiscal period	Towa Pharmaceutical, J-Dolph Pharmaceutical, Daichi Kasei, Greencaps Pharmaceutical					Sunsho Pharmaceutical				
	2024/03 1Q Results		2024/03 Full-year Plan			2024/03 1Q Results		2024/03 Full-year Plan		
Item	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)
Net sales	36,524	100.0	148,000	100.0	24.7	6,480	100.0	23,900	100.0	27.1
Cost of sales	21,660	59.3	86,600	58.5	25.0	4,916	75.9	19,500	81.6	25.2
SGA	10,271	28.1	46,800	31.6	21.9	965	14.9	3,200	13.4	30.2
Segment profit	4,592	12.6	14,600	9.9	31.5	598	9.2	1,200	5.0	49.9

- Notes: 1. The first three-month period for Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.

# Outline of financial results for 2024/03 1Q – Progress rate (Overseas segment)

- **Net sales:** The progress rate was good due to foreign exchange impacts despite the sales suspension of products of certain manufacturing licensees in the U.S.
- **Segment profit:** Loss decreased compared to the plan due to a reduction in SGA spending.

(JPY million, %)

Fiscal period	Overseas segment (Towa HD)							
	2024/03 1Q Results		2024/03 First Half Plan			2024/03 Full-year Plan		
Item	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)
Net sales	11,579	100.0	21,800	100.0	53.1	44,600	100.0	26.0
Cost of sales	7,962	68.8	15,000	68.8	53.1	30,500	68.4	26.1
SGA	3,645	31.5	6,900	31.7	52.8	14,000	31.4	26.0
Segment profit (loss)	- 28	- 0.2	- 100	- 0.5	-	100	0.2	-

Exchange rate (TTM) EUR 1	Rate during 2024/03 1Q	Assumed rate for 2024/03
		JPY 149.47

- Notes: 1. The first three-month period for Towa HD is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.

# Outline of financial results for 2024/03 1Q – Progress rate

## (Overseas segment, by region)


(JPY million, %)

Fiscal period	Towa HD Europe					Towa HD U.S.				
	2024/03 1Q Results		2024/03 Full-year Plan			2024/03 1Q Results		2024/03 Full-year Plan		
Item	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)	(JPY million)	Percentage of net sales (%)	(JPY million)	Percentage of net sales (%)	Progress rate (%)
Net sales	6,668	100.0	25,000	100.0	26.7	4,911	100.0	19,600	100.0	25.1
Cost of sales	4,478	67.2	16,200	64.8	27.6	3,484	71.0	14,300	73.0	24.4
SGA	2,582	38.7	9,900	39.6	26.1	1,062	21.6	4,100	20.9	25.9
Segment profit (loss)	– 392	– 5.9	– 1,100	– 4.4	–	364	7.4	1,200	6.1	30.3

Exchange rate (TTM) EUR 1	Rate during 2024/03 1Q	Assumed rate for 2024/03
		JPY 149.47

- Notes: 1. The first three-month period for Towa HD is from April 1, 2023 to June 30, 2023.  
2. Goodwill amortization is not included.

# Trend of R&D expenses (Consolidated)



- Notes: 1. The consolidated fiscal year ended March 31, 2023 for Towa HD and Sunsho Pharmaceutical is the 15-month period from January 1, 2022 to March 31, 2023.  
 2. 2021/03–2022/03 does not include the results of Sunsho Pharmaceutical.



# Table of contents

1. Outline of financial results for 2023/03
2. Outline of financial results for 2023/03  
– Progress rate
- 3. Balance sheets, capital expenditure and depreciation**

# Balance sheets (Consolidated)


(JPY million)

Item	2023/06	2023/03	Change	Item	2023/06	2023/03	Change
Cash and deposits	30,817	24,257	+ 6,559	Notes and accounts payable - trade	18,272	17,272	+ 1,000
Notes and accounts receivable - trade	51,254	46,795	+ 4,459	Electronically recorded obligations - operating	10,410	18,798	- 8,388
Electronically recorded monetary claims - operating	8,513	7,777	+ 736	Short-term borrowings	3,921	3,677	+ 243
Merchandise and finished goods	47,043	44,457	+ 2,586	Current portion of long-term borrowings	9,302	7,527	+ 1,774
Other inventories	50,490	48,470	+ 2,019	Notes and accounts payable - equipment	16,428	14,012	+ 2,415
Other current assets	13,452	11,232	+ 2,219	Other current liabilities	18,412	17,240	+ 1,172
<b>Total current assets</b>	<b>201,571</b>	<b>182,990</b>	<b>+ 18,581</b>	<b>Total current liabilities</b>	<b>76,747</b>	<b>78,529</b>	<b>- 1,781</b>
Buildings and structures, net	55,783	56,190	- 407	Long-term borrowings	167,829	150,314	+ 17,515
Machinery, equipment and vehicles, net	18,160	18,966	- 805	Other non-current liabilities	5,595	5,609	- 14
Construction in progress	37,078	31,155	+ 5,922	<b>Total non-current liabilities</b>	<b>173,424</b>	<b>155,923</b>	<b>+ 17,501</b>
Goodwill	34,049	34,613	- 563	<b>Total liabilities</b>	<b>250,172</b>	<b>234,453</b>	<b>+ 15,719</b>
Other non-current assets	47,526	47,431	+ 95	Foreign currency translation adjustment	12,420	8,608	+ 3,812
<b>Total non-current assets</b>	<b>192,598</b>	<b>188,357</b>	<b>+ 4,240</b>	Other net assets	131,576	128,286	+ 3,290
<b>Total assets</b>	<b>394,170</b>	<b>371,347</b>	<b>+ 22,822</b>	<b>Total net assets</b>	<b>143,997</b>	<b>136,894</b>	<b>+ 7,102</b>
				<b>Total liabilities and net assets</b>	<b>394,170</b>	<b>371,347</b>	<b>+ 22,822</b>

Exchange rate at end of period (TTM)	2023/06	2023/03
EUR 1	JPY 157.60	JPY 145.72

Notes: 1. The first three-month period for Towa HD and Sunsho Pharmaceutical is from April 1, 2023 to June 30, 2023.

# Capital expenditure and depreciation (Consolidated)



Notes:

- Capital expenditure includes the purchase of property, plant and equipment, and intangible assets.
- Depreciation includes the R&D expenses portion.
- Depreciation does not include goodwill amortization for Towa HD and Sunsho Pharmaceutical.
- 2021/03–2022/03 does not include the results of Sunsho Pharmaceutical.
- The consolidated fiscal year ended March 31, 2023 for Towa HD and Sunsho Pharmaceutical is the 15-month period from January 1, 2022 to March 31, 2023.

- Capex (Towa HD)
- Capex (Yamagata Plant)
- Capex (Okayama Plant)
- Capex (other)
- Depreciation (Sunsho Pharmaceutical)
- Depreciation (Towa HD)
- Depreciation (domestic)

**Forward-looking statements are based on targets and projections and do not offer commitments or guarantees.  
Please be aware that results may differ from the forecasts.**

**Contact:**

---

**Investor Relations Group, Public Relations and Investor Relations Department, Towa Pharmaceutical Co., Ltd.**

**[ir@towayakuhin.co.jp](mailto:ir@towayakuhin.co.jp) TEL. +81-6-6900-9102 FAX. +81-6-7177-4960**